Casgevy: First-ever CRISPR-based medicine gets FDA nod for beta-thalassemia treatment...

Go [here]( to opt-out of our email list or mark as [SPAM](. Please add us to your address book or [whitelist us](. Directions for whitelisting are [here](. --------------------------------------------------------------- ---------------------------------------------------------------  FEATURED [Casgevy: First-ever CRISPR-based medicine gets FDA nod for beta-thalassemia treatment](  The Food and Drug Administration (FDA) of the United States has given a green flag to a medication to treat sickle cell disease – Casgevy, to treat another blood disorder named beta-thalassemia. To highlight, the sickle cell treatment was approved by the FDA in December 2023.Casgevy is the first-ever CRISPR-based medicine approved for usage in the United States.  [Read More >>](  --------------------------------------------------------------- THIS WEEK'S TOP STORIES ...  [Measles threat spreads across the US: Virginia reports suspected cases, urges caution for travelers]( [LA County faces tripledemic crisis as respiratory illnesses surge post-holiday season](  [EXCLUSIVE: Session on 'Disease X' raises global concerns – Are we on Brink of Global Crisis?]( ~Health Experts --------------------------------------------------------------- You opted in to receive these emails when you requested information or entered one of our contests. You can [Manage Subcription]( here if you do not want to receive these emails any longer. To help make sure we make it into your inbox, add support@primehealthexperts.com to your address book.     This email was sent to {EMAIL} by support@primehealthexperts.com primehealthexperts.com c/o Patriot Brands LLC 296 Beauvoir Rd, Biloxi, MS 39531  [1-Click Unsubscribe]( | [Edit Profile]( | [Manage Subscriptions]( | [Report Spam]( Â